APEX-BREAST01
What it tests: TQB2102 versus chemotherapy in HER2-low recurrent or metastatic breast cancer. Randomized phase 3 study.

Listen to Oncology Here & Now
What it tests: TQB2102 versus chemotherapy in HER2-low recurrent or metastatic breast cancer. Randomized phase 3 study.
The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.